The risk of upper gastrointestinal bleeding associated with concomitant proton pump inhibitor administration during dual antiplatelet therapy with aspirin and prasugrel: a retrospective single-center study
Abstract Objective Dual‐antiplatelet therapy (DAPT) and proton pump inhibitor (PPI) are frequently prescribed after percutaneous coronary intervention (PCI) with drug-eluting stents (DES) placement. However, studies that evaluate the optimal PPI when used as primary prevention in patients without a...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-11-01
|
| Series: | Journal of Pharmaceutical Health Care and Sciences |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40780-024-00398-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846147588629200896 |
|---|---|
| author | Yutaro Ide Go Morikawa Kyohei Yoshida Yuki Takano Ken Kubota Katsuko Okazawa Takeo Yasu |
| author_facet | Yutaro Ide Go Morikawa Kyohei Yoshida Yuki Takano Ken Kubota Katsuko Okazawa Takeo Yasu |
| author_sort | Yutaro Ide |
| collection | DOAJ |
| description | Abstract Objective Dual‐antiplatelet therapy (DAPT) and proton pump inhibitor (PPI) are frequently prescribed after percutaneous coronary intervention (PCI) with drug-eluting stents (DES) placement. However, studies that evaluate the optimal PPI when used as primary prevention in patients without a history of peptic ulcer disease or upper gastrointestinal bleeding (UGIB), particularly in the context of DAPT involving prasugrel, are lacking. This study aimed to assess the efficacy and safety of PPI use in preventing UGIB in this patient population. Methods This study included patients who underwent PCI with coronary stent placement for acute coronary syndrome or stable angina at our institution from January 2015 to December 2020. Eligible patients started DAPT with aspirin and prasugrel and concomitantly received PPI therapy (lansoprazole or esomeprazole), with a follow-up period of two years. The primary endpoint was UGIB incidence, diagnosed during follow-up, serving as an efficacy measure. Secondary endpoints included the assessment of major bleeding (as defined by the Thrombolysis in Myocardial Infarction major bleeding criteria) and clinically relevant non-major bleeding events. Safety outcomes focused on adverse event incidence attributable to PPI use. Results Among the 165 patients analyzed, 109 and 56 were included in the lansoprazole and esomeprazole groups, respectively, with cumulative incidence of UGIB at 96 weeks of 0.9% (1/109) and 3.6% (2/56). No significant differences in terms of major bleeding events or other bleeding outcomes were observed between the two groups. Adverse events related to PPI use were reported as diarrhea/soft stools in 7 (6%) cases and thrombocytopenia in 1 (1%) case in the lansoprazole group, whereas no such events were observed in the esomeprazole group. No clinically significant hematologic or biochemical abnormalities were reported. Conclusion This study evaluated the efficacy and safety of PPIs in combination with DAPT, including prasugrel, following PCI, and suggests that lansoprazole and esomeprazole may offer comparable efficacy in preventing UGIB. |
| format | Article |
| id | doaj-art-62dcecd12cad4fe292fbca75cde2c07b |
| institution | Kabale University |
| issn | 2055-0294 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Pharmaceutical Health Care and Sciences |
| spelling | doaj-art-62dcecd12cad4fe292fbca75cde2c07b2024-12-01T12:37:39ZengBMCJournal of Pharmaceutical Health Care and Sciences2055-02942024-11-011011710.1186/s40780-024-00398-yThe risk of upper gastrointestinal bleeding associated with concomitant proton pump inhibitor administration during dual antiplatelet therapy with aspirin and prasugrel: a retrospective single-center studyYutaro Ide0Go Morikawa1Kyohei Yoshida2Yuki Takano3Ken Kubota4Katsuko Okazawa5Takeo Yasu6Department of Pharmacy, Hokushin General HospitalDepartment of Pharmacy, Hokushin General HospitalDepartment of Pharmacy, Hokushin General HospitalDepartment of Pharmacy, Hokushin General HospitalDepartment of Pharmacy, Hokushin General HospitalDepartment of Pharmacy, Hokushin General HospitalDepartment of Medicinal Therapy Research, Pharmaceutical Education and Research Center, Meiji Pharmaceutical UniversityAbstract Objective Dual‐antiplatelet therapy (DAPT) and proton pump inhibitor (PPI) are frequently prescribed after percutaneous coronary intervention (PCI) with drug-eluting stents (DES) placement. However, studies that evaluate the optimal PPI when used as primary prevention in patients without a history of peptic ulcer disease or upper gastrointestinal bleeding (UGIB), particularly in the context of DAPT involving prasugrel, are lacking. This study aimed to assess the efficacy and safety of PPI use in preventing UGIB in this patient population. Methods This study included patients who underwent PCI with coronary stent placement for acute coronary syndrome or stable angina at our institution from January 2015 to December 2020. Eligible patients started DAPT with aspirin and prasugrel and concomitantly received PPI therapy (lansoprazole or esomeprazole), with a follow-up period of two years. The primary endpoint was UGIB incidence, diagnosed during follow-up, serving as an efficacy measure. Secondary endpoints included the assessment of major bleeding (as defined by the Thrombolysis in Myocardial Infarction major bleeding criteria) and clinically relevant non-major bleeding events. Safety outcomes focused on adverse event incidence attributable to PPI use. Results Among the 165 patients analyzed, 109 and 56 were included in the lansoprazole and esomeprazole groups, respectively, with cumulative incidence of UGIB at 96 weeks of 0.9% (1/109) and 3.6% (2/56). No significant differences in terms of major bleeding events or other bleeding outcomes were observed between the two groups. Adverse events related to PPI use were reported as diarrhea/soft stools in 7 (6%) cases and thrombocytopenia in 1 (1%) case in the lansoprazole group, whereas no such events were observed in the esomeprazole group. No clinically significant hematologic or biochemical abnormalities were reported. Conclusion This study evaluated the efficacy and safety of PPIs in combination with DAPT, including prasugrel, following PCI, and suggests that lansoprazole and esomeprazole may offer comparable efficacy in preventing UGIB.https://doi.org/10.1186/s40780-024-00398-yPCIDAPTPPIUGBIPrasugrelLansoprazole |
| spellingShingle | Yutaro Ide Go Morikawa Kyohei Yoshida Yuki Takano Ken Kubota Katsuko Okazawa Takeo Yasu The risk of upper gastrointestinal bleeding associated with concomitant proton pump inhibitor administration during dual antiplatelet therapy with aspirin and prasugrel: a retrospective single-center study Journal of Pharmaceutical Health Care and Sciences PCI DAPT PPI UGBI Prasugrel Lansoprazole |
| title | The risk of upper gastrointestinal bleeding associated with concomitant proton pump inhibitor administration during dual antiplatelet therapy with aspirin and prasugrel: a retrospective single-center study |
| title_full | The risk of upper gastrointestinal bleeding associated with concomitant proton pump inhibitor administration during dual antiplatelet therapy with aspirin and prasugrel: a retrospective single-center study |
| title_fullStr | The risk of upper gastrointestinal bleeding associated with concomitant proton pump inhibitor administration during dual antiplatelet therapy with aspirin and prasugrel: a retrospective single-center study |
| title_full_unstemmed | The risk of upper gastrointestinal bleeding associated with concomitant proton pump inhibitor administration during dual antiplatelet therapy with aspirin and prasugrel: a retrospective single-center study |
| title_short | The risk of upper gastrointestinal bleeding associated with concomitant proton pump inhibitor administration during dual antiplatelet therapy with aspirin and prasugrel: a retrospective single-center study |
| title_sort | risk of upper gastrointestinal bleeding associated with concomitant proton pump inhibitor administration during dual antiplatelet therapy with aspirin and prasugrel a retrospective single center study |
| topic | PCI DAPT PPI UGBI Prasugrel Lansoprazole |
| url | https://doi.org/10.1186/s40780-024-00398-y |
| work_keys_str_mv | AT yutaroide theriskofuppergastrointestinalbleedingassociatedwithconcomitantprotonpumpinhibitoradministrationduringdualantiplatelettherapywithaspirinandprasugrelaretrospectivesinglecenterstudy AT gomorikawa theriskofuppergastrointestinalbleedingassociatedwithconcomitantprotonpumpinhibitoradministrationduringdualantiplatelettherapywithaspirinandprasugrelaretrospectivesinglecenterstudy AT kyoheiyoshida theriskofuppergastrointestinalbleedingassociatedwithconcomitantprotonpumpinhibitoradministrationduringdualantiplatelettherapywithaspirinandprasugrelaretrospectivesinglecenterstudy AT yukitakano theriskofuppergastrointestinalbleedingassociatedwithconcomitantprotonpumpinhibitoradministrationduringdualantiplatelettherapywithaspirinandprasugrelaretrospectivesinglecenterstudy AT kenkubota theriskofuppergastrointestinalbleedingassociatedwithconcomitantprotonpumpinhibitoradministrationduringdualantiplatelettherapywithaspirinandprasugrelaretrospectivesinglecenterstudy AT katsukookazawa theriskofuppergastrointestinalbleedingassociatedwithconcomitantprotonpumpinhibitoradministrationduringdualantiplatelettherapywithaspirinandprasugrelaretrospectivesinglecenterstudy AT takeoyasu theriskofuppergastrointestinalbleedingassociatedwithconcomitantprotonpumpinhibitoradministrationduringdualantiplatelettherapywithaspirinandprasugrelaretrospectivesinglecenterstudy AT yutaroide riskofuppergastrointestinalbleedingassociatedwithconcomitantprotonpumpinhibitoradministrationduringdualantiplatelettherapywithaspirinandprasugrelaretrospectivesinglecenterstudy AT gomorikawa riskofuppergastrointestinalbleedingassociatedwithconcomitantprotonpumpinhibitoradministrationduringdualantiplatelettherapywithaspirinandprasugrelaretrospectivesinglecenterstudy AT kyoheiyoshida riskofuppergastrointestinalbleedingassociatedwithconcomitantprotonpumpinhibitoradministrationduringdualantiplatelettherapywithaspirinandprasugrelaretrospectivesinglecenterstudy AT yukitakano riskofuppergastrointestinalbleedingassociatedwithconcomitantprotonpumpinhibitoradministrationduringdualantiplatelettherapywithaspirinandprasugrelaretrospectivesinglecenterstudy AT kenkubota riskofuppergastrointestinalbleedingassociatedwithconcomitantprotonpumpinhibitoradministrationduringdualantiplatelettherapywithaspirinandprasugrelaretrospectivesinglecenterstudy AT katsukookazawa riskofuppergastrointestinalbleedingassociatedwithconcomitantprotonpumpinhibitoradministrationduringdualantiplatelettherapywithaspirinandprasugrelaretrospectivesinglecenterstudy AT takeoyasu riskofuppergastrointestinalbleedingassociatedwithconcomitantprotonpumpinhibitoradministrationduringdualantiplatelettherapywithaspirinandprasugrelaretrospectivesinglecenterstudy |